GlassScriptPhysician profile
Amol Sharma
NPI 1124276761
$5,067.23
in general payments reported to CMS, 2019-2025
15 companies · $473 in 2025
The $473 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $147 · 2021: $3,210 · 2022: $196 · 2023: $458 · 2024: $445 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,376.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $3,210.00 | 2021 | |
| Ardelyx, INC. | $522.67 | 2022-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $412.44 | 2022-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $199.84 | 2023-2025 | |
| Abbvie INC. | $138.16 | 2019 | |
| Lucid Diagnostics INC. | $119.46 | 2023 | |
| Qol Medical, LLC | $118.98 | 2023-2024 | Sucraid, Sucraid |
| Steris Corporation | $96.51 | 2020 | |
| Atmo Biosciences INC | $82.62 | 2025 | Atmo Biosciences |
| Astrazeneca Pharmaceuticals LP | $50.06 | 2020 | |
| Phathom Pharmaceuticals, INC. | $38.34 | 2024 | Voquezna |
| Celgene Corporation | $21.03 | 2024 | Zeposia |
| Olympus America INC. | $20.48 | 2022 | |
| Pfizer INC. | $18.85 | 2023 | |
| Conmed Corporation | $17.79 | 2023 | System 2450 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amol Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.